Cover Image
市場調查報告書

躁鬱症:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析

Bipolar Disorder Disease Coverage to 2024

出版商 Datamonitor Healthcare 商品編碼 365212
出版日期 內容資訊 英文 349 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
躁鬱症:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析 Bipolar Disorder Disease Coverage to 2024
出版日期: 2018年04月09日 內容資訊: 英文 349 Pages
簡介

躁鬱症的治療藥的市場上,現在學名藥壓倒了市場大半,那妨礙市場成長。可破除這個情形的開發中產品還沒出現。

本報告提供躁鬱症的已上市/臨床實驗中 (開發平台上)的治療藥相關分析,各產品的市場規模的估計值,左右今後的市場趨勢的諸要素,及最高成長率領域,與其他的精神疾病 (的治療藥) 的差異,標準的治療方法,主要的未滿足需求等相關調查。

市場預測:躁鬱症

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • Abilify (Aripiprazole)
  • Abilify Maintena (Aripiprazole)
  • Latuda (Lurasidone)
  • Risperdal Consta (risperidone)
  • Saphris (asenapin)
  • Seroquel/Seroquel XR (quetiapine fumarate)
  • Vraylar (cariprazine)
  • 一次調查技術

治療方法:躁鬱症

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢
  • 躁鬱症相關的未滿足需求

流行病學:美國、日本、歐洲的躁鬱症

  • 摘要整理
  • 疾病定義
  • 全球各地的趨勢的差異
  • 風險要素
  • 併發症
  • 資訊來源、分析方法
  • 市場預測
  • 預測:雙極性I型障礙
  • 預測:雙極性II型障礙
  • 流行病學者的見解
  • 分析的優勢與限制
  • 附錄

已上市藥物:躁鬱症

  • 摘要整理
  • 產品概要
  • 其他的已上市藥物
  • 產品簡介:Abilify
  • 產品簡介:Geodon
  • 產品簡介:Lamictal
  • 產品簡介:Latuda
  • 產品簡介:Risperdal/Risperdal Consta
  • 產品簡介:Saphris
  • 產品簡介:Seroquel/Seroquel XR
  • 產品簡介:Vraylar
  • 產品簡介:Zyprexa

開發中產品:氣喘

  • 摘要整理
  • 臨床實驗開發平台概要
  • 分析目標產品簡介
  • 臨床實驗的設計
  • 未來的治療方法
  • 最近臨床實驗中止的藥物
  • 產品簡介 (最後階段):ITI-007

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC13101

Disease Overview

Bipolar disorder is a psychiatric disorder characterized by unusual shifts in mood, energy, activity levels, and the ability to carry out everyday tasks. Patients with the disorder may experience periods of mania (an overly joyful or overexcited state) followed by periods of depression (feelings of extreme sadness or hopelessness). Symptoms of bipolar disorder are severe and can result in damaged relationships, poor educational or occupational performance, and even suicide.

Market Snapshot

Temporary downturn in bipolar market value will be recouped by oral drug approvals/launches and sales momentum of LAIs.

The complexity of bipolar disorder is yet to be unlocked, contributing to a lack of episode-tailored treatment strategies.

Forecasted growth in the total prevalence of bipolar I disorder and bipolar II disorder will be driven by demographics.

New brand Vraylar is yet to distinguish itself, but its long patent life permits ample time to improve product positioning.

Otsuka initiates Phase III development of Rexulti for bipolar mania without proof-of-concept trial.

CONTENTS

12 FORECAST: BIPOLAR DISORDER (Published on 09 April 2018)

12 OVERVIEW

13 EXECUTIVE SUMMARY

15 MARKET OVERVIEW AND TRENDS

29 MARKET DEFINITION AND METHODOLOGY

42 ABILIFY (ARIPIPRAZOLE)

45 ABILIFY MAINTENA (ARIPIPRAZOLE)

48 GEODON (ZIPRASIDONE)

51 LAMICTAL/LAMICTAL XR (LAMOTRIGINE)

54 LATUDA (LURASIDONE)

57 LUMATEPERONE

60 RISPERDAL CONSTA (RISPERIDONE)

63 SAPHRIS (ASENAPINE)

67 SEROQUEL/SEROQUEL XR (QUETIAPINE)

70 VRAYLAR (CARIPRAZINE)

73 ZYPREXA (OLANZAPINE)

76 PRIMARY RESEARCH METHODOLOGY

78 TREATMENT: BIPOLAR DISORDER (Published on 21 August 2017)

78 OVERVIEW

79 EXECUTIVE SUMMARY

80 PRIMARY RESEARCH METHODOLOGY

82 DISEASE DEFINITION AND DIAGNOSIS

89 PATIENT SEGMENTATION

95 CURRENT TREATMENT OPTIONS

112 TREATMENT DYNAMICS

137 UNMET NEEDS IN BIPOLAR DISORDER

143 EPIDEMIOLOGY: BIPOLAR DISORDER IN THE US, JAPAN, AND 5EU (Published on 17 July 2017)

143 OVERVIEW

144 EXECUTIVE SUMMARY

145 DISEASE BACKGROUND

148 SOURCES AND METHODOLOGY

155 FORECAST: BIPOLAR I DISORDER

162 FORECAST: BIPOLAR II DISORDER

169 EPIDEMIOLOGIST INSIGHT

178 STRENGTHS AND LIMITATIONS

180 APPENDIX: ADDITIONAL SOURCES

181 MARKETED DRUGS: BIPOLAR DISORDER (Published on 09 April 2018)

181 OVERVIEW

182 EXECUTIVE SUMMARY

184 PRODUCT OVERVIEW

186 PRODUCT PROFILE: ABILIFY

200 PRODUCT PROFILE: ABILIFY MAINTENA

209 PRODUCT PROFILE: GEODON

224 PRODUCT PROFILE: LAMICTAL

234 PRODUCT PROFILE: LATUDA

250 PRODUCT PROFILE: RISPERDAL CONSTA

261 PRODUCT PROFILE: SAPHRIS

279 PRODUCT PROFILE: SEROQUEL/SEROQUEL XR

299 PRODUCT PROFILE: VRAYLAR

312 PRODUCT PROFILE: ZYPREXA

327 PIPELINE: BIPOLAR DISORDER (Published on 09 April 2018)

327 OVERVIEW

328 EXECUTIVE SUMMARY

329 CLINICAL PIPELINE OVERVIEW

330 PRODUCT PROFILE (LATE STAGE): ALKS 3831

335 PRODUCT PROFILE (LATE STAGE): REXULTI

340 PRODUCT PROFILE (LATE STAGE): LUMATEPERONE

LIST OF FIGURES

  • 15 Figure 1: Bipolar disorder market sales across the US, Japan, and five major EU markets, by country, 2017-26
  • 17 Figure 2: Growth dynamics of the bipolar disorder market across the US, Japan, and five major EU markets, by country, 2017-26
  • 18 Figure 3: Bipolar disorder market sales across the US, Japan, and five major EU markets, by disease phase, 2017-26
  • 22 Figure 4: Bipolar disorder market sales across the US, Japan, and five major EU markets, by drug class, 2017-26
  • 25 Figure 5: Sales of selected competing LAI brands across the US, Japan, and five major EU markets, 2017-26
  • 27 Figure 6: Sales of selected competing bipolar depression brands across the US, Japan, and five major EU markets, 2017-26
  • 32 Figure 7: Methodology flow for Datamonitor Healthcare's bipolar disorder patient-based forecast
  • 34 Figure 8: Price sources and calculations, by country
  • 43 Figure 9: Abilify sales for bipolar disorder across the US, Japan, and five major EU markets, by country, 2017-26
  • 46 Figure 10: Abilify Maintena sales for bipolar disorder across the US, Japan, and five major EU markets, by country, 2017-26
  • 49 Figure 11: Geodon/Zeldox sales for bipolar disorder across the US, Germany, Italy, and Spain, by country, 2017-26
  • 52 Figure 12: Lamictal/Lamictal XR sales for bipolar disorder across the US, Japan, and five major EU markets, by country, 2017-26
  • 55 Figure 13: Latuda sales for bipolar disorder across the US, Japan, Germany, Italy, Spain, and the UK, by country, 2017-26
  • 58 Figure 14: Lumateperone sales for bipolar disorder in the US, 2017-26
  • 61 Figure 15: Risperdal Consta sales for bipolar disorder across the US, Japan, and major EU markets, by country, 2017-26
  • 64 Figure 16: Saphris/Sycrest sales for bipolar disorder across the US, Japan, and major EU markets, by country, 2017-26
  • 68 Figure 17: Seroquel/Seroquel XR sales for bipolar disorder across the US, Japan, and five major EU markets, by country, 2017-26
  • 71 Figure 18: Vraylar sales for bipolar disorder in the US and five major EU markets, by country, 2017-26
  • 74 Figure 19: Zyprexa sales for bipolar disorder across the US, Japan, and five major EU markets, by country, 2017-26
  • 83 Figure 20: DSM-V diagnostic criteria for mood episodes based on symptoms
  • 84 Figure 21: DSM-V diagnostic criteria for bipolar disorder subtypes
  • 86 Figure 22: Diagnosis rates for bipolar disorder in the US, Japan, and five major EU markets, by country
  • 90 Figure 23: Segmentation of bipolar disorder patients by disease phase in the US, Japan, and five major EU markets, by country
  • 92 Figure 24: Segmentation of bipolar disorder patients by line of therapy across the US, Japan, and five major EU markets
  • 95 Figure 25: Drug treatment rate for bipolar disorder in the US, Japan, and five major EU markets, by country
  • 98 Figure 26: Psychological interventions for bipolar disorder
  • 104 Figure 27: Guidelines for bipolar disorder treatment
  • 105 Figure 28: Drug classes recommended in bipolar disorder treatment guidelines, by disease phase and line of therapy
  • 106 Figure 29: Guideline recommendations for acute mania by line of treatment
  • 108 Figure 30: Guideline recommendations for acute depression by line of treatment
  • 110 Figure 31: Guideline recommendations for maintenance therapy by line of treatment
  • 112 Figure 32: Top five overall class regimens across the US, Japan, and five major EU markets, by bipolar disorder disease phase and line of therapy
  • 117 Figure 33: Top five overall drug treatments across the US, Japan, and five major EU markets, by bipolar disorder disease phase and line of therapy
  • 121 Figure 34: Top five first-line drug treatments for mania in the US, Japan, and five major EU markets, by country
  • 124 Figure 35: Top five second-line and beyond drug treatments for mania in the US, Japan, and five major EU markets, by country
  • 126 Figure 36: Top five first-line drug treatments for depression in the US, Japan, and five major EU markets, by country
  • 128 Figure 37: Top five second-line and beyond drug treatments for bipolar depression in the US, Japan, and five major EU markets, by country
  • 130 Figure 38: Top five first-line drug treatments for maintenance therapy in the US, Japan, and five major EU markets, by country
  • 132 Figure 39: Top five second-line and beyond drug treatments for maintenance therapy in the US, Japan, and five major EU markets, by country
  • 134 Figure 40: Compliance rates of bipolar disorder patients in the US, Japan, and five major EU markets, by country and disease phase
  • 137 Figure 41: Key unmet needs for bipolar disorder, 2017
  • 158 Figure 42: Trend in total prevalent cases of bipolar I disorder in the US, Japan, and five major EU markets, by country, 2016-36
  • 159 Figure 43: Absolute change in total prevalent cases of bipolar I disorder in the US, Japan, and five major EU markets, by country, 2016-36
  • 165 Figure 44: Trend in total prevalent cases of bipolar II disorder in the US, Japan, and five major EU markets, by country, 2016-36
  • 166 Figure 45: Absolute change in total prevalent cases of bipolar II disorder in the US, Japan, and five major EU markets, by country, 2016-36
  • 194 Figure 46: Abilify for bipolar disorder - SWOT analysis
  • 195 Figure 47: Datamonitor Healthcare's drug assessment summary for Abilify in bipolar disorder
  • 196 Figure 48: Datamonitor Healthcare's drug assessment summary for Abilify in bipolar disorder
  • 204 Figure 49: Abilify Maintena for bipolar disorder - SWOT analysis
  • 205 Figure 50: Datamonitor Healthcare's drug assessment summary for Abilify Maintena in bipolar disorder
  • 206 Figure 51: Datamonitor Healthcare's drug assessment summary for Abilify Maintena in bipolar disorder
  • 219 Figure 52: Geodon for bipolar disorder - SWOT analysis
  • 220 Figure 53: Datamonitor Healthcare's drug assessment summary for Geodon in bipolar disorder
  • 221 Figure 54: Datamonitor Healthcare's drug assessment summary for Geodon in bipolar disorder
  • 229 Figure 55: Lamictal for bipolar disorder - SWOT analysis
  • 230 Figure 56: Datamonitor Healthcare's drug assessment summary for Lamictal in bipolar disorder
  • 231 Figure 57: Datamonitor Healthcare's drug assessment summary for Lamictal in bipolar disorder
  • 245 Figure 58: Latuda for bipolar disorder - SWOT analysis
  • 246 Figure 59: Datamonitor Healthcare's drug assessment summary for Latuda in bipolar disorder
  • 247 Figure 60: Datamonitor Healthcare's drug assessment summary for Latuda in bipolar disorder
  • 256 Figure 61: Risperdal Consta for bipolar disorder - SWOT analysis
  • 257 Figure 62: Datamonitor Healthcare's drug assessment summary for Risperdal Consta in bipolar disorder
  • 258 Figure 63: Datamonitor Healthcare's drug assessment summary for Risperdal Consta in bipolar disorder
  • 274 Figure 64: Saphris for bipolar disorder - SWOT analysis
  • 275 Figure 65: Datamonitor Healthcare's drug assessment summary for Saphris in bipolar disorder
  • 276 Figure 66: Datamonitor Healthcare's drug assessment summary for Saphris in bipolar disorder
  • 293 Figure 67: Seroquel/Seroquel XR for bipolar disorder - SWOT analysis
  • 294 Figure 68: Datamonitor Healthcare's drug assessment summary for Seroquel/Seroquel XR in bipolar disorder
  • 295 Figure 69: Datamonitor Healthcare's drug assessment summary for Seroquel/Seroquel XR in bipolar disorder
  • 307 Figure 70: Vraylar for bipolar disorder - SWOT analysis
  • 308 Figure 71: Datamonitor Healthcare's drug assessment summary for Vraylar in bipolar disorder
  • 309 Figure 72: Datamonitor Healthcare's drug assessment summary for Vraylar in bipolar disorder
  • 322 Figure 73: Zyprexa for bipolar disorder - SWOT analysis
  • 323 Figure 74: Datamonitor Healthcare's drug assessment summary for Zyprexa in bipolar disorder
  • 324 Figure 75: Datamonitor Healthcare's drug assessment summary for Zyprexa in bipolar disorder
  • 333 Figure 76: ALKS 3831 for bipolar disorder - SWOT analysis
  • 339 Figure 77: Rexulti for bipolar disorder - SWOT analysis
  • 344 Figure 78: Lumateperone for bipolar disorder - SWOT analysis
  • 345 Figure 79: Datamonitor Healthcare's drug assessment summary for lumateperone in bipolar disorder
  • 346 Figure 80: Datamonitor Healthcare's drug assessment summary for lumateperone in bipolar disorder

LIST OF TABLES

  • 16 Table 1: Bipolar disorder market sales across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 19 Table 2: Bipolar disorder market sales across the US, Japan, and five major EU markets, by disease phase and line of therapy ($m), 2017-26
  • 23 Table 3: Bipolar disorder market sales across the US, Japan, and five major EU markets, by drug class ($m), 2017-26
  • 26 Table 4: Sales of selected competing LAI brands across the US, Japan, and five major EU markets ($m), 2017-26
  • 28 Table 5: Sales of selected competing bipolar depression brands across the US, Japan, and five major EU markets ($m), 2017-26
  • 30 Table 6: Summary of drug classes and molecules included in Datamonitor Healthcare's bipolar disorder patient-based forecast
  • 35 Table 7: Exchange rates used for calculating prices
  • 36 Table 8: Estimated patent expiry/loss of exclusivity dates for key marketed brands in bipolar disorder, by country, 2017-26
  • 39 Table 9: Estimated launch and approval dates for key products in bipolar disorder, by country, 2017-26
  • 44 Table 10: Abilify sales for bipolar disorder across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 47 Table 11: Abilify Maintena sales for bipolar disorder across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 50 Table 12: Geodon/Zeldox sales for bipolar disorder across the US, Germany, Italy, and Spain, by country ($m), 2017-26
  • 53 Table 13: Lamictal/Lamictal XR sales for bipolar disorder across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 56 Table 14: Latuda sales for bipolar disorder across the US, Japan, Germany, Italy, Spain, and the UK, by country ($m), 2017-26
  • 59 Table 15: Lumateperone sales for bipolar disorder in the US ($m), 2017-26
  • 62 Table 16: Risperdal Consta sales for bipolar disorder across the US, Japan, and major EU markets, by country ($m), 2017-26
  • 65 Table 17: Saphris/Sycrest sales for bipolar disorder across the US, Japan, and major EU markets, by country ($m), 2017-26
  • 69 Table 18: Seroquel/Seroquel XR sales for bipolar disorder across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 72 Table 19: Vraylar sales for bipolar disorder in the US and five major EU markets, by country ($m), 2017-26
  • 75 Table 20: Zyprexa sales for bipolar disorder across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 76 Table 21: Physicians surveyed for the bipolar disorder primary research study, 2017
  • 80 Table 22: Physicians surveyed for the bipolar disorder primary research study, 2017
  • 86 Table 23: Diagnosis rates for bipolar disorder in the US, Japan, and five major EU markets (%), by country
  • 90 Table 24: Segmentation of bipolar disorder patients by disease phase in the US, Japan, and five major EU markets (%), by country
  • 93 Table 25: Segmentation of bipolar disorder patients by disease phase and line of therapy in the US, Japan, and five major EU markets (%), by country
  • 96 Table 26: Drug treatment rate for bipolar disorder in the US, Japan, and five major EU markets (%), by country and disease phase
  • 100 Table 27: Leading therapies for bipolar disorder
  • 113 Table 28: Leading class regimens according to patient share across the US, Japan, and five major EU markets (%), by bipolar disorder disease phase and line of therapy
  • 118 Table 29: Leading drug treatments according to patient share across the US, Japan, and five major EU markets (%), by bipolar disorder disease phase and line of therapy
  • 120 Table 30: Monotherapy and combination therapy use of lithium across the US, Japan, and five major EU markets (%), by bipolar disorder disease phase and line of therapy
  • 122 Table 31: First-line drug treatments for mania in the US, Japan, and five major EU markets (%), by country
  • 125 Table 32: Second-line and beyond drug treatments for mania in the US, Japan, and five major EU markets (%), by country
  • 127 Table 33: First-line drug treatments for depression in the US, Japan, and five major EU markets (%), by country
  • 129 Table 34: Second-line and beyond drug treatments for bipolar depression in the US, Japan, and five major EU markets (%), by country
  • 131 Table 35: First-line drug treatments for maintenance therapy in the US, Japan, and five major EU markets (%), by country
  • 133 Table 36: Second-line and beyond drug treatments for maintenance therapy in the US, Japan, and five major EU markets (%), by country
  • 134 Table 37: Compliance rates of bipolar disorder patients in the US, Japan, and five major EU markets (%), by country and disease phase
  • 145 Table 38: DSM-IV definitions of bipolar disorder subtypes
  • 149 Table 39: Sources used for the epidemiological analysis of bipolar disorder in the US, Japan, and five major EU markets, by country
  • 151 Table 40: Sources not used for the epidemiological analysis of bipolar disorder in the US, Japan, and five major EU markets, by country
  • 156 Table 41: Total prevalent cases of bipolar I disorder in the US, Japan, and five major EU markets, by country, 2016-36
  • 160 Table 42: Age-specific total prevalent cases of bipolar I disorder in the US, Japan, and five major EU markets, by country, 2016
  • 161 Table 43: Gender-specific total prevalent cases of bipolar I disorder in the US, Japan, and five major EU markets, by country, 2016
  • 163 Table 44: Total prevalent cases of bipolar II disorder in the US, Japan, and five major EU markets, by country, 2016-36
  • 167 Table 45: Age-specific total prevalent cases of bipolar II disorder in the US, Japan, and five major EU markets, by country, 2016
  • 168 Table 46: Gender-specific total prevalent cases of bipolar II disorder in the US, Japan, and five major EU markets, by country, 2016
  • 171 Table 47: Prevalence of psychiatric co-morbidities among patients with bipolar disorder, by type
  • 172 Table 48: Total prevalent cases of bipolar I disorder with psychiatric co-morbidities in the US, Japan, and five major EU markets, by country and type, 2016
  • 173 Table 49: Total prevalent cases of bipolar II disorder with psychiatric co-morbidities in the US, Japan, and five major EU markets, by country and type, 2016
  • 174 Table 50: Prevalence of medical co-morbidities among patients with bipolar disorder, by co-morbidity
  • 175 Table 51: Total prevalent cases of bipolar I disorder with medical co-morbidities in the US, Japan, and five major EU markets, by country and co-morbidity, 2016
  • 177 Table 52: Total prevalent cases of bipolar II disorder with medical co-morbidities in the US, Japan, and five major EU markets, by country and co-morbidity, 2016
  • 185 Table 53: Key marketed drugs for bipolar disorder
  • 187 Table 54: Abilify bipolar disorder indication approvals
  • 188 Table 55: Abilify drug profile
  • 190 Table 56: Overview of key clinical trial data for Abilify in bipolar disorder
  • 193 Table 57: Commonly observed adverse reactions in clinical trials of Abilify in bipolar mania
  • 200 Table 58: Abilify Maintena bipolar disorder indication approvals
  • 201 Table 59: Abilify Maintena drug profile
  • 202 Table 60: Overview of key clinical trial data for Abilify Maintena in bipolar disorder
  • 203 Table 61: Commonly observed adverse reactions in clinical trials of Abilify Maintena in bipolar I disorder
  • 209 Table 62: Geodon bipolar disorder indication approvals
  • 210 Table 63: Geodon drug profile
  • 212 Table 64: Overview of key clinical trial data for Geodon in bipolar disorder
  • 214 Table 65: Treatment-emergent adverse reactions in ≥5% of Geodon-treated adult patients with bipolar mania in doubleblind, placebo-controlled trials
  • 216 Table 66: Geodon ongoing late-phase clinical trials as a therapy in children and adolescents with bipolar I disorder
  • 218 Table 67: Overview of key clinical trial data for Geodon in bipolar depression
  • 224 Table 68: Lamictal bipolar disorder indication approvals
  • 225 Table 69: Lamictal drug profile
  • 226 Table 70: Overview of clinical trial data for Lamictal in maintenance treatment of adults with bipolar I disorder
  • 227 Table 71: Key side effects reported in clinical trials of Lamictal as a maintenance therapy in adults with bipolar I disorder
  • 228 Table 72: Selected clinical trials of Lamictal in bipolar depression
  • 235 Table 73: Latuda bipolar disorder indication approvals
  • 236 Table 74: Latuda drug profile
  • 238 Table 75: Overview of pivotal Phase III PREVAIL trials of Latuda in adults with bipolar depression
  • 239 Table 76: Adverse reactions in ≥5% of Latuda-treated adult patients in bipolar depression studies
  • 240 Table 77: Overview of the Phase III ILLUMINATE trial of Latuda in adolescents and children with bipolar depression
  • 241 Table 78: Adverse reactions in ≥5% of Latuda-treated pediatric patients in bipolar depression studies
  • 242 Table 79: Overview of key Japanese clinical trial data for Latuda in bipolar disorder
  • 244 Table 80: Overview of clinical trial data for Latuda in maintenance treatment of bipolar I disorder
  • 250 Table 81: Risperdal Consta bipolar disorder indication approvals
  • 251 Table 82: Risperdal Consta drug profile
  • 253 Table 83: Risperdal Consta pivotal trial data in bipolar disorder
  • 255 Table 84: Adverse reactions in ≥5% of Risperdal Consta-treated adult patients with bipolar disorder
  • 262 Table 85: Saphris bipolar disorder indication approvals
  • 263 Table 86: Saphris drug profile
  • 265 Table 87: Saphris pivotal trial data for the acute treatment of manic episodes in bipolar disorder
  • 268 Table 88: Adverse events in ≥5% of Saphris-treated adult patients with bipolar mania in double-blind, placebo-controlled trials
  • 269 Table 89: Adverse events in ≥5% of Saphris-treated adult patients with bipolar mania in a double-blind, placebo-controlled trial
  • 270 Table 90: Trial data for Saphris as a maintenance therapy
  • 272 Table 91: Overview of key pivotal trial data for Saphris in pediatric bipolar disorder patients
  • 273 Table 92: Adverse reactions in ≥5% of Saphris-treated pediatric patients (10-17 years) with bipolar mania in a double-blind, placebo-controlled trial
  • 280 Table 93: Seroquel/Seroquel XR bipolar disorder indication approvals
  • 281 Table 94: Seroquel/Seroquel XR drug profile
  • 283 Table 95: Overview of key pivotal trial data for Seroquel in adult bipolar disorder patients
  • 287 Table 96: Adverse reactions in ≥5% of Seroquel-treated adult patients in Phase III trials for bipolar disorder
  • 289 Table 97: Overview of key pivotal trial data for Seroquel in pediatric bipolar disorder patients
  • 291 Table 98: Overview of key pivotal trial data for Seroquel XR in adult bipolar disorder
  • 292 Table 99: Key side effects (≥5%) reported in clinical trials of Seroquel XR in bipolar disorder
  • 300 Table 100: Vraylar bipolar disorder indication approvals
  • 301 Table 101: Vraylar drug profile
  • 302 Table 102: Overview of key pivotal trial data for Vraylar in bipolar disorder
  • 304 Table 103: Key side effects (≥5%) reported in clinical trials of Vraylar monotherapy for bipolar mania
  • 306 Table 104: Vraylar Phase III trials in bipolar depression
  • 312 Table 105: Zyprexa bipolar disorder indication approvals
  • 314 Table 106: Zyprexa drug profile
  • 316 Table 107: Overview of key pivotal trial data for Zyprexa in bipolar disorder
  • 320 Table 108: Adverse reactions reported in ≥5% of patients in six-week clinical trials of Zyprexa as an adjunct to lithium or valproate in adult bipolar disorder (manic/mixed episodes)
  • 321 Table 109: Key side effects reported in clinical trials of Zyprexa in bipolar disorder
  • 329 Table 110: Profiled pipeline products in development for bipolar disorder
  • 331 Table 111: ALKS 3831 drug profile
  • 332 Table 112: ALKS 3831 Phase III trials in bipolar disorder
  • 336 Table 113: Rexulti drug profile
  • 337 Table 114: Rexulti Phase III trials in bipolar mania
  • 339 Table 115: Rexulti Phase IV trial in bipolar depression
  • 341 Table 116: Lumateperone drug profile
  • 342 Table 117: Lumateperone Phase III trials in bipolar disorder

 

Back to Top